Signalomic signatures enlighten drug profiling

Nature Chemical Biology

Volumn 2, Issue 6, 2006, Pages 295-296

  Abraham, Robert T ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; YELLOW FLUORESCENT PROTEIN;

CELL; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVITY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; GENETIC ANALYSIS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 33646936138     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio0606-295     Document Type: Short Survey

References (7)

1. Frantz, S. Nature 437, 942-943 (2005).
2. Garber, K. Nat. Biotechnol. 24, 127-130 (2006).
3. MacDonald, M.L. et al. Nat. Chem. Biol. 2, 329-337 (2006).
4. Remy, I. & Michnick, S.W. Proc. Natl. Acad. Sci. USA 96, 5394-5399 (1999).
5. Luker, K.E. et al. Proc. Natl. Acad. Sci. USA 101, 12288-12293 (2004).
6. Piehler, J. Curr. Opin. Struct. Biol. 15, 4-14 (2005).
7. Kola, I. & Landis, J. Nat. Rev. Drug Discov. 3, 711-715 (2004).